MagnetOs™ Bone Graft
A bone graft like no other
MagnetOs™ is a bone graft like no other: thanks to its NeedleGrip™ surface technology, it grows bone even in soft tissues.* This surface technology provides traction for our body’s vitally important ‘pro-healing’ immune cells (M2 macrophages).†‡ [1,2]
This in turn, unlocks previously untapped potential to stimulate stem cells – and form new bone throughout the graft.†§[3-6]
The growing body of science behind NeedleGrip is called osteoimmunology. But for surgeons and their patients it means one thing: a more predictable fusion.†¶[5,6]
1. Duan, et al. eCM. 2019;37:60-73.
2. Van Dijk, et al. eCM. 2021;41:756-73.
3. Van Dijk, et al. JOR Spine. 2018;e1039.
4. Van Dijk, et al. J Biomed Mater Res. Part B: Appl Biomater. 2019;107(6):2080-2090.
5. Van Dijk, et al. Clin Spine Surg. 2020;33(6):E276-E287.
6. Data on file.
5. Van Dijk, et al. Clin Spine Surg. 2020;33(6):E276-E287.
6. Data on file.
2. Van Dijk, et al. eCM. 2021;41:756-73.
6. Data on file.
2. Van Dijk, et al. eCM. 2021;41:756-73.
3. Van Dijk, et al. JOR Spine. 2018;e1039.
4. Van Dijk, et al. J Biomed Mater Res. Part B: Appl Biomater. 2019;107(6):2080-2090.
5. Van Dijk, et al. Clin Spine Surg. 2020;33(6):E276-E287.
6. Data on file.
12. Yu, et al. J Cell Biochem. 2016;117(7):1511-1521.
13. Ligouri, et al. Cell Mol Immunol. 2021;18(3):711-722.
6. Data on file.
13. Ligouri, et al. Cell Mol Immunol. 2021;18(3):711-722.
14. Zhang, et al. Cell Tissue Res. 2017.
15. Arosarena, et al. J Cell Physiol. 2011;226(11):2943-2952.
6. Data on file.
13. Ligouri, et al. Cell Mol Immunol. 2021;18(3):711-722.
MagnetOs Mechanism of Action
1. Polarise
Circulating immune cells (monocytes) differentiate into macrophages that are subsequently polarised, by the submicron needle-shaped features of MagnetOs’ NeedleGrip surface.
As a result, they become the pro-healing, anti-inflammatory M2 macrophage phenotype.[2,6]
2. Regenerate
In natural bone homeostasis, it is well established that M2 macrophages play a critical role.
M2 macrophages communicate with local stem – and progenitor cells via secretion of regenerative signalling factors, including osteoactivin and BMP-2.[6,12,13]
These signalling factors induce mesenchymal stem cells to migrate, proliferate, and differentiate into osteoblasts that lay down osteoid.[6,13-15]
Endothelial cells are stimulated to form capillaries that deliver nutrients and yet more osteogenic cells to the site of repair.[6,13]
3. Propagate
Non-unions tend to happen in the core of large-span defects, as seen in spinal fusions.
NeedleGrip propagates bone in this core region – by interacting directly and indirectly with circulating osteogenic cells – rather than only from the outside-in via creeping edge repair.[2-5]
MagnetOs: the evidence
MagnetOs is proven to be equivalent to the gold standard of autograft for spinal fusions.[2,4,5,16] It has been used in more than 25,000 fusion surgeries to date and is supported by an unprecedented blend of scientific, pre-clinical and clinical studies through Project Fusion: our global research program, where science and clinical evidence meet.
Kuros is dedicated to reliably translate evidence from benchtop through to patient. To see how, review our extensive list of studies including peer-reviewed results from our latest Level I clinical trial published in Spine.[16]
Level I Clinical Evidence: MAXA
A randomized, intra-patient controlled trial of MagnetOs Granules versus autograft in instrumented posterolateral spinal fusion
Peer-reviewed research paper published in Spine (June 2024)[16]
2. Van Dijk, et al. eCM. 2021;41:756-73.
4. Van Dijk, et al. J Biomed Mater Res. Part B: Appl Biomater. 2019;107(6):2080-2090.
5. Van Dijk, et al. Clin Spine Surg. 2020;33(6):E276-E287.
16. Stempels, et al. Spine. 2024;49(19):1323-1331.
16. Stempels, et al. Spine. 2024;49(19):1323-1331.
MagnetOs Granules
MagnetOs™ Granules is our original advanced bone graft based on the submicron needle-shaped NeedleGrip™ surface technology. It forms the foundation of all MagnetOs formulations and is the driver of our mechanism of action.
The scientists from Kuros Biosciences have spent more than a decade studying and refining the technology and surface science to harness the power of osteoimmunology.
These continuous efforts to mimic the best features of biologically robust autograft bone have led to the creation of MagnetOs as it is today.
1. Data on file.
2. Duan, et al. eCM. 2019;37:60-73.
3. Van Dijk, et al. eCM. 2021;41:756-73.
4. Van Dijk, et al. J Immunol Regen Med. 2023;19:100070.
1. Data on file.
5. Van Dijk, et al. JOR Spine. 2018;e1039.
6. Van Dijk, et al. J Biomed Mater Res. Part B: Appl Biomater. 2019;107(6)2080-2090.
Strong foundation & proven
MagnetOs Granules is the basis for all MagnetOs formulations and has been 510(k)-cleared since 2017. This foundational technology has paved the way for more than 25,000 patients treated and counting; all supported by an unprecedented blend of scientific, preclinical, and clinical studies through our global research program, Project Fusion.[1]
Harnessing the immune system
MagnetOs is capable of polarising macrophages from the M1 pro-inflammatory to the M2 pro-healing phenotype, which is known to influence bone growth through secretion of proteins such as BMP-2. MagnetOs has been shown in pre-clinical studies to form bone even in soft tissue* without added cells or growth factors.[2-4]†‡ These features combine to make MagnetOs an active player in providing predictable fusions.
Equivalent to autograft
In fact, MagnetOs Granules as a standalone bone graft reached higher fusion rates than the gold standard of autograft. This is based on results of an observer blinded, randomised, controlled, intrapatient, multi-centre clinical trial of instrumented posterolateral fusions, as assessed by fine-cut CT scans at one year follow-up.[1]
The MagnetOs Granules technology is also proven to be equivalent to autograft for spinal fusions in multiple pre-clinical models.[1,5,6]†¶
MagnetOs Putty
Speed and efficiency are essential in the operating room, which is why we designed MagnetOs™ Putty to be easy to store, handle, and apply.
MagnetOs Putty delivers all the benefits of our established MagnetOs family thanks to our unique NeedleGrip™ surface technology – which grows bone even in soft tissue* without added cells or growth factors.[1-3]†‡
Simply warm it in your hands, mold into the desired shape, and use it to fill bony voids spaces any way you need, including in the intervertebral disc space or posterolateral spine.[4]^^
1. Duan, et al. eCM. 2019;37:60-73.
2. Van Dijk, et al. eCM. 2021;41:756-73.
3. Van Dijk, et al. J Immunol Regen Med. 2023;19:100070.
4. Please refer to the Instructions for Use (IFU) MagnetOs Putty (US) for a full list of indications, contraindications, precautions and warnings.
5. Instructions for Use (IFU) MagnetOs Putty.
5. Instructions for Use (IFU) MagnetOs Putty.
6. Instructions for Use (IFU) MagnetOs Granules.
7. Instructions for Use (IFU) MagnetOs Easypack Putty
Easy to store, handle, & apply
Unlike frozen allografts, MagnetOs can be stored at ambient temperature (max. 45ºC) with no special requirements.[5] MagnetOs Putty is ready-to-use straight out of the package with no preparation time or thawing needed. The carrier is designed to maximise handling properties, so you can twist, tear, and mold it into any shape desired before implantation and remain confident that it will stay in place and resist migration and irrigation.[5]
Free of animal & human tissues
MagnetOs Putty contains no animal or human-derived tissue – just like MagnetOs Granules and MagnetOs Easypack Putty.[5-7] This alleviates patient concerns during consent for use of allograft or xenograft-derived products in surgery.
One product for Spine & Orthopaedics
This is a versatile graft that is indicated for standalone use at all levels of the posterolateral spine, in the intervertebral disc space and in the extremities and pelvis. [5] §
Kuros Biosciences is a fast-growing leader in the development of fusion biologics that ease the burden of back pain. With locations in the United States, Switzerland and the Netherlands, the company is listed on the SIX Swiss Exchange.
The company’s first commercial product, MagnetOs™, is a unique bone graft that has already been used successfully across four continents. For more information on the company, its products and pipeline, visit kurosbio.com.
Disclaimers
* In large animal models.
† Results from in vitro or in vivo laboratory testing may not be predictive of clinical experience in humans. For important safety and intended use information please visit kurosbio.com/eifu.
‡ MagnetOs is not cleared by the FDA or TGA as an osteoinductive bone graft.
§ For a 510(k)-cleared synthetic bone graft.
¶ MagnetOs has been proven to generate more predictable fusions than two commercially available alternatives in an ovine model of posterolateral fusion.
^^ When used in intervertebral body fusion procedures, MagnetOs must be used with an intervertebral body fusion device cleared by FDA for use with a bone void filler.
Revolution Surgical Pty Ltd
4/22 Rowood Road, Prospect NSW 2148
ABN: 63 165 643 434
© 2018- Revolution Surgical
Website by: 